Distinct Cytokine Profiles of Systemic-onset Juvenile Idiopathic Arthritis-associated Macrophage Activation Syndrome with Particular Emphasis on the Role of Interleukin-18 in Its Pathogenesis
Overview
Authors
Affiliations
Objectives: To compare the pro-inflammatory cytokine profiles and the cytokine kinetics in patients with secondary macrophage activation syndrome (MAS) due to systemic-onset juvenile idiopathic arthritis (s-JIA) and in both active and inactive disease states of s-JIA (but no MAS), with those demonstrated in EBV-induced haemophagocytic lymphohistiocytosis (HLH) and Kawasaki disease (KD), and to investigate the significance of IL-18 in the pathogenesis of s-JIA.
Methods: Five patients with MAS complicating s-JIA (MAS/s-JIA), 10 with HLH due to EBV infection (EBV-HLH), 22 with KD and 28 healthy controls were analysed. Cytokine concentrations (IL-18, IL-6, neopterin and TNF-alpha receptor Types I and II) were quantified in serum by ELISA. Results were compared with clinical features of MAS/s-JIA, including ferritin concentrations.
Results: Serum IL-18 concentrations in MAS/s-JIA patients were significantly higher than those in EBV-HLH or KD patients (P < 0.05). Serum IL-6 concentrations in KD patients were significantly higher than those in EBV-HLH or MAS/s-JIA patients. Serum neopterin concentrations in EBV-HLH patients were significantly higher than those in MAS/s-JIA or KD patients. Serum IL-18 correlated positively with the following measurements of disease activity: CRP, ferritin, lactate dehydrogenase and other cytokines (P < 0.05). Serum concentrations of IL-18 in s-JIA patients remained elevated in the inactive phase of disease, whereas clinical parameters and other cytokines normalized.
Conclusions: IL-18 may be an important mediator in s-JIA. Although serum Il-18 concentrations correlated with markers of the disease activity, IL-18 concentrations remained elevated even when other markers of disease activity normalized. Serum IL-18 concentration may be a promising indicator of the disease activity. The cytokine release pattern in MAS/HLH is different among patients with different aetiologies. Monitoring the cytokine profile, including IL-18, may be useful for differentiation of MAS/HLH and evaluation of disease activity in s-JIA.
Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A J Hematol Oncol. 2024; 17(1):106.
PMID: 39511607 PMC: 11542428. DOI: 10.1186/s13045-024-01621-x.
De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S Ann Rheum Dis. 2024; 83(12):1748-1761.
PMID: 39317414 PMC: 11671913. DOI: 10.1136/ard-2024-225853.
Anti-Interferon-γ Therapy for Cytokine Storm Syndromes.
Behrens E, De Benedetti F Adv Exp Med Biol. 2024; 1448:573-582.
PMID: 39117840 DOI: 10.1007/978-3-031-59815-9_38.
Autoinflammatory Contributors to Cytokine Storm.
Canna S Adv Exp Med Biol. 2024; 1448:385-397.
PMID: 39117828 DOI: 10.1007/978-3-031-59815-9_26.
Kawasaki Disease-Associated Cytokine Storm Syndrome.
Tsoukas P, Yeung R Adv Exp Med Biol. 2024; 1448:365-383.
PMID: 39117827 DOI: 10.1007/978-3-031-59815-9_25.